Veeva Systems, IQVIA, & the Pharma Sales Flow
Former VP, Global Accounts at Veeva Systems
inpractise.com/articles/veeva-systems-iqvia-and-the-pharma-sales-flow
Veeva Systems, IQVIA, & the Pharma Sales Flow(April 16, 2024)
Former VP, Global Accounts at Veeva Systems
The executive managed a top 10 pharma customer account at Veeva for 5 years after working with Salesforce leading sales across media and IT end markets.
Interview Transcript
This is a snippet of the transcript, sign up to read more.
How come they've done that though? Because I thought in the Veeva contract that they couldn't partner with someone who's a competitor or is did they only partner when Veeva announced they were going to shift off to Vault?
Yes, it's a good question. I don't know the ins and outs of the contract. It was interesting when Salesforce allowed OCE to build a couple of years back. That's the question. Maybe that was speculative, but maybe that's when Veeva thought, well, hey, if they're going to let someone else do it, it's our time to really push forward with the plan. So that could have been the case. I don't know how that one worked out because it was interesting. I was working there at that time. I was managing global accounts that we were competing against OCE. We almost lost one of them. They committed to OCE. OCE could not deliver, so they ended up having to stay with Veeva. But from a headspace or from a commitment perspective, we were told by this top 20 pharma, we're going to OCE.
This is a snippet of the transcript, sign up to read more.
Related Content
Veeva Compass and OpenData vs IQVIA
Former Director at Veeva Systems
Salesforce: MuleSoft Strategy
Former SVP at MuleSoft
Clarivate: Management, M&A, & the One Clarivate Strategy
Former Vice President at Clarivate
Alteryx: Customer Profiles, GTM Strategy & Product Roadmap
Former Strategic Account Director at Alteryx
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.